关注我们
ZH
ZH

我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI，丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表，并设置隐藏和个性化的提醒。

全部新闻 / 二月 2017

归档

✕
16 二月 2017
3954
HIV DNA declines rapidly in some infants who start ART soon after birth

HIV DNA declines rapidly in some infants who start ART soon after birth

Two new South African studies have shown that HIV-positive infants who start antiretroviral therapy (ART) within days of birth can rapidly reduce their viral load and viral DNA. While this is not the same as curing HIV, researchers do consider reducing viral DNA a crucial ...
16 二月 2017
4423
Most at risk for undiagnosed HIV in the US: young MSM, Black MSM, and Hispanic/Latino MSM

Most at risk for undiagnosed HIV in the US: young MSM, Black MSM, and Hispanic/Latino MSM

New CDC data on HIV in men who have sex with men (MSM) show that in the years 2008-2014, the number of new HIV infections in young MSM (ages 25-34) and in Hispanic/Latino MSM increased significantly, while the levels of HIV infection among Black MSM, who are most at risk ...
16 二月 2017
3723
Report: Obamacare increased HIV patients' coverage through Medicaid

Report: Obamacare increased HIV patients' coverage through Medicaid

According to a Kaiser Family Foundation report based on data from the U.S. Centers for Disease Control and Prevention's Medical Monitoring Project, significant increases in health insurance coverage for people with HIV occurred under the Affordable Care Act (also known as ...
15 二月 2017
3932
ECDC: The demographics of HIV diagnosis among migrants are shifting

ECDC: The demographics of HIV diagnosis among migrants are shifting

According to the European Centre for Disease Control (ECDC), HIV diagnoses among migrants from Latin America, the Caribbean, and central and Eastern Europe now outnumber diagnoses among migrants from sub-Saharan Africa. Across Europe, 38% of people diagnosed with HIV were ...
15 二月 2017
4266
Gilead's new HIV drug more successful than Glaxo's dolutegravir

Gilead's new HIV drug more successful than Glaxo's dolutegravir

The results of a mid-stage clinical trial show that bictegravir, a next-generation integrase inhibitor manufactured by Gilead Sciences, was more successful in suppressing the HIV virus in newly diagnosed patients than dolutegravir, rival company GlaxoSmithKline's drug. These ...
15 二月 2017
3699
Study: Iran has lowest rates of HCV in Middle East

Study: Iran has lowest rates of HCV in Middle East

A recent analysis of 12 population studies showed that the seroprevalence of the hepatitis C virus in Iran is lower than in other Middle Eastern countries. Among the general population, the rate was 0.6% (95% CI, 0.4-0.8), with an overall rate of true viremia of 0.4% (95% ...
14 二月 2017
3711
Study: migrants start HIV treatment later

Study: migrants start HIV treatment later

According to a study of over 150,000 people living with HIV in western Europe, migrants from other parts of the world tend to start cART (combination antiretroviral treatment) later than those born in western Europe.
14 二月 2017
4160
Ghana to produce ART drugs locally

Ghana to produce ART drugs locally

Ghana's government has committed to support local pharmaceutical companies to manufacture anti-retroviral drugs for persons living with HIV and AIDS. During a visit from the Executive Director of the Joint United Nations Programme on HIV and AIDS (UNAIDS), Michael Sidibe, ...
14 二月 2017
4062
NHS introduces postcode lottery, new restrictions on IVF

NHS introduces postcode lottery, new restrictions on IVF

Great Britain's cash-strapped NHS has introduced a postcode lottery for IVF, along with new limitations on who can receive the treatment. The restrictions vary by region, but many allow the treatment only in “exceptional” circumstances, for instance when a man could infect ...
13 二月 2017
3761
New Zealand: Government to fund PrEP

New Zealand: Government to fund PrEP

The New Zealand Labour party made a pledge to fund a pre-exposure prophylaxis medication (PrEP) that reduces the risk of acquiring HIV by more than 90 percent. The once-a-day pill regimen is designed for people who are HIV-negative, and, according to major studies, if taken ...
我们在此网站上使用cookies以增强您的浏览体验。
继续浏览网页即表示您同意我们在网站上使用默认的cookies设置。